CiaranelloAL, WalenskyRP, SaxPE, et al.Access to medications and medical care after participation in HIV clinical trials: A systematic review of trial protocols and informed consent documents. HIV Clin Trials, 2009; 10:13–24.
2.
El-SadrW, LundgrenJ, NeatonJ, et al.Strategies for management of antiretroviral therapy study G. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 2006; 355:2283–2296.
3.
PaceC, GradyC, WendlerD, et al.Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Human Retrovir, 2006; 22:837–841.
4.
KiwanukaJ, Mukulu WailaJ, Muhindo KahunguM, et al.Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda. PLoS One, 2020; 15:e0217606.
5.
SinghH, RaoSV, KakkarAK, et al.Posttrial access to medical interventions: Intricacies, challenges, and solutions. Int J Appl Basic Med Res, 2019; 9:3.
6.
LunesR, UribeMV, TorresJB, et al.Who should pay for the continuity of post-trial health care treatments?. Int J Equity Health, 2019; 18:1–6.
7.
MerrittM, GradyC. Reciprocity and post-trial access for participants in antiretroviral therapy trials. AIDS, 2006; 20:1791–1794.
8.
SofaerN, ThiessenC, GooldSD, et al.Subjects' views of obligations to ensure post-trial access to drugs, care and information: Qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study. J Med Ethics, 2009; 35:183–188.
9.
LamaJR, BrezakA, DobbinsJG, et al.Design strategy of the Sabes Study: Diagnosis and treatment of early HIV infection among men who have sex with men and transgender women in Lima, Peru, 2013–2017. Am J Epidemiol, 2018; 187:1577–1585.
10.
LamaJR, Bender IgnacioRA, AlfaroR, et al.Clinical and immunologic outcomes after immediate or deferred antiretroviral therapy initiation during primary human immunodeficiency virus infection: The Sabes randomized clinical study. Clin Infect Dis, 2021; 72:1042–1050.
11.
MassanellaM, Bender IgnacioRA, LamaJ, et al.Long-term effects of early antiretroviral initiation on HIV reservoir markers: A longitudinal analysis of the MERLIN clinical study. Lancet Microbe, 2021; 2:e198–e209.
12.
ShahS, ElmerS, GradyC. Planning for posttrial access to antiretroviral treatment for research participants in developing countries. Am J Public Health, 2009; 99:1556–1562.
13.
LawrenceDS, HirschLA. Decolonising global health: Transnational research partnerships under the spotlight. Int Health, 2020; 12:518–523.
14.
MogakaOeF, StewartJ, BukusiE. Why and for whom are we decolonising global health?. Lancet Global Health, 2021; 9:e1359–e1360.
15.
DooleyKE, KaplanR, MwelaseN, et al.Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: A multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis, 2020; 70:549–556.
